Wantai Bio announced on January 15 that it expects to achieve net profit attributable to the parent company's owners of 86 million to 120 million yuan in 2024, a year-on-year decrease of 90.38% to 93.11%; it is expected that the net profit attributable to the parent company's owners after deducting non-recurring gains and losses in 2024 will be -155 million to -220 million yuan.

During the reporting period, the company's vaccine segment was affected by market adjustments, government centralized procurement and the expansion of the age of the nine-valent HPV vaccine, and sales were not as expected. The revenue and profit of the vaccine segment dropped sharply, resulting in a net loss. At the same time, the company promoted international market sales through multiple methods and channels, and overseas operating income increased by 55% compared with the same period last year.

The diagnostics segment benefited from the accelerated advancement of major related projects such as assembly lines, and cooperation with the top 300 hospitals in the country. Excluding COVID-19 diagnosis-related businesses, sales revenue and profits grew rapidly compared to the same period last year.

https://finance.eastmoney.com/a/202501153297988032.html